The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the forecast period (2023-2030). A significant the market growth is anticipated to come from the extensive clinical trial pipeline for peptide drug conjugates, coupled with increased research and development expenditures for PDC development and the rising burden of disease globally. For instance, in July 2021, Takeda Pharmaceutical Co., Ltd., collaborated with PeptideDream, to invest $3.5 billion to develop peptide drugs for neuromuscular disease. Furthermore, pharmaceutical companies are developing PDCs as focused therapeutic treatments for diseases such as cancer, viral infections, and metabolic disorders. Further, the increasing agreement and acquisition for Peptide Drug Conjugates is projected to drive market growth by promoting increased acceptance and usage of these devices.
Browse the full report description of “Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Type (Diagnostic and Therapeutic), and by Product (Melflufen, Lutetium, ANG1005, BT1718 and CBX-12), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/peptide-drug-conjugates-market
• In November 2022, Exelixis, Inc., and Cybrexa Therapeutics Inc., entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex™ exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
• In June 2019, Peptidream Inc., a public Kanagawa-based biopharmaceutical company entered into a new Peptide Drug Conjugate collaboration agreement with Swiss-based Novartis AG. Under the agreement, PeptiDream used its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic peptides for use as PDCs against multiple targets of interest selected by Novartis. Under the terms of the agreement, PeptiDream received an undisclosed upfront payment, R&D funding payments, and eligible to receive additional pre-clinical, clinical, approval, and commercial sales milestones.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Product
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Oncopeptides AB, and Novartis AG, among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Peptide Drug Conjugates Market Report Segment
By Type
By Product
Global Peptide Drug Conjugates Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/peptide-drug-conjugates-market